Key Insights

Highlights

Success Rate

72% trial completion

Published Results

14 trials with published results (11%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.0%

14 terminated out of 127 trials

Success Rate

72.0%

-14.5% vs benchmark

Late-Stage Pipeline

9%

11 trials in Phase 3/4

Results Transparency

39%

14 of 36 completed with results

Key Signals

14 with results72% success14 terminated

Data Visualizations

Phase Distribution

109Total
Not Applicable (50)
Early P 1 (4)
P 1 (14)
P 2 (30)
P 3 (10)
P 4 (1)

Trial Status

Recruiting40
Completed36
Active Not Recruiting25
Terminated14
Not Yet Recruiting7
Withdrawn3

Trial Success Rate

72.0%

Benchmark: 86.5%

Based on 36 completed trials

Clinical Trials (127)

Showing 20 of 20 trials
NCT02918474Not ApplicableRecruiting

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

NCT06058377Phase 3RecruitingPrimary

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT04678414Active Not Recruiting

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer

NCT06538389Phase 2Suspended

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT07443943Phase 2Recruiting

A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial

NCT07391774Phase 3Not Yet RecruitingPrimary

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT05568472Not ApplicableActive Not Recruiting

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

NCT04993313Not ApplicableActive Not Recruiting

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

NCT05417867Recruiting

Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

NCT06401889Recruiting

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

NCT05379153Phase 3Not Yet Recruiting

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

NCT04266249Phase 2Active Not RecruitingPrimary

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT03786354Not ApplicableActive Not RecruitingPrimary

Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer

NCT07474090Not ApplicableNot Yet Recruiting

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial

NCT05874297Not ApplicableNot Yet Recruiting

Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer

NCT04001829Phase 2Active Not Recruiting

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT05417308Early Phase 1Recruiting

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

NCT07460752Phase 2Not Yet Recruiting

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

NCT01334021Phase 2Active Not Recruiting

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

Scroll to load more

Research Network

Activity Timeline